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Abstract
 
Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease characterized
by flares of high morbidity. Using oligonucleotide microarrays, we now show that active SLE
can be distinguished by a remarkably homogeneous gene expression pattern with overexpression
of granulopoiesis-related and interferon (IFN)-induced genes. Using the most stringent statis-
tical analysis (Bonferroni correction), 15 genes were found highly up-regulated in SLE pa-
tients, 14 of which are targets of IFN and one, defensin DEFA-3, a major product of imma-
ture granulocytes. A more liberal correction (Benjamini and Hochberg correction) yielded 18
additional genes, 12 of which are IFN-regulated and 4 granulocyte-specific. Indeed immature
neutrophils were identified in a large fraction of SLE patients white blood cells. High dose
glucocorticoids, a standard treatment of disease flares, shuts down the interferon signature, fur-
ther supporting the role of this cytokine in SLE. The expression of 10 genes correlated with
disease activity according to the SLEDAI. The most striking correlation (P 
 
  
 
0.001, 
 
r
 
 
 
  
 
0.55)
was found with the formyl peptide receptor-like 1 protein that mediates chemotactic activities
of defensins. Therefore, while the IFN signature confirms the central role of this cytokine in
SLE, microarray analysis of blood cells reveals that immature granulocytes may be involved in
SLE pathogenesis.
Key words: microarray • immature granulocytes • glucocorticoid • leukocytes • autoimmunity
 
Introduction
 
Systemic lupus erythematosus (SLE)
 
*
 
 affects multiple or-
gans, including the skin, vessels, kidneys, and central ner-
vous system (1, 2). SLE etiopathogenesis has challenged
investigators for many years. It is believed that the en-
vironment, e.g., viral infections, acts in the context of a
wide array of susceptibility genes. Human SLE appears
linked to at least 6 gene loci and numerous mouse genetic
mutants show SLE-like syndromes (3). This disease, where
tolerance to self-components is broken in a systemic fash-
ion, is currently viewed as a dysregulation of T–B cell in-
teractions (4–7). SLE patients paradoxically display poly-
clonal hypergammaglobulinemia concomitantly with B and
T lymphopenia (8, 9). Indeed, human SLE is characterized
by high titers of autoantibodies of a wide range of specifici-
ties, including nuclear components, DNA, and nucleo-
somes (10–12). Vasculitis and kidney failure are thought to
be immune complex-mediated while other symptoms such
as thrombocytopenia are viewed as direct antibody-medi-
ated depletion. Yet, these alterations represent end-points
of a dysregulated immune system. Therefore, understand-
ing the early stages of the disease might lead to the devel-
opment of better therapies, which currently are symptom-
atic and based on nonspecific immunosuppression i.e.,
glucocorticoids and chemotherapy. Dendritic cells (DCs;
reference 13) are being recognized as critical in the mainte-
nance of peripheral tolerance (14). Therefore, we turned
our attention to their potential alteration in pediatric SLE, a
disease of high morbidity/mortality. Accordingly, we dem-
onstrated that a fraction of patients display in their blood
stream monocytes with properties of DCs, namely the abil-
ity to induce allogeneic naive T cells to proliferate (MLR;
reference 15). Furthermore, the serum of some patients in-
duced the differentiation of normal monocytes into DCs,
an effect mediated by IFN-
 
 
 
. This led us to consider that
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Abbreviations used in this paper:
 
 DC, dendritic cell; JCA, juvenile
chronic arthritis; SLE, systemic lupus erythematosus.T
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SLE may be driven by unabated IFN production that acti-
vates monocytes into mature DCs able to capture dying
cells and present their antigens to autoreactive T/B cells.
Yet, only a fraction of patients display circulating IFN-
 
 
 
(16), thereby raising the question of whether this reflects
disease heterogeneity. Because IFN-
 
 
 
 may represent a ma-
jor therapeutic target in SLE, as TNF does in arthritis (17),
we approached this question by analyzing the genes ex-
pressed by patient leukocytes using oligonucleotide mi-
croarray technology (18–20). Here we demonstrate that
blood mononuclear cells from active SLE patients overex-
press IFN-regulated and granulopoiesis-specific genes. The
IFN signature is extinguished by treatment with high dose
intravenous steroids, further pointing to this cytokine as a
specific target for therapeutic intervention.
 
Materials and Methods
 
Messenger RNA Samples.
 
After informed consent (IRB no.
0199017), blood was obtained from pediatric patients who satis-
fied diagnostic criteria of the American College of Rheumatology
(ACR) for SLE and Juvenile Chronic Arthritis (poly-articular,
pauci-articular, and systemic) and controls (children visiting the
clinic for reasons other than autoimmunity or infectious diseases).
Disease activity was assessed by the SLEDAI activity index and
determined the day of blood draw. Blood leukocytes were iso-
lated on Ficoll gradient and immediately processed for RNA ex-
traction using the RNeasy kit (QIAGEN) according to the man-
ufacturer’s instructions.
 
Flow Cytometry and Cell Cultures.
 
A fraction of patients cells
was retained for flow cytometry analysis including the determina-
tion of T cells, B cells, plasmablasts (CD20
 
 
 
CD19 low CD38
high), monocytes as described earlier (9) and DCs (DC kit; Bec-
ton Dickinson). Leukocytes from healthy adults were cultured in
RPMI enriched with 5% fetal calf serum for 6 h with or without
1,000 U/ml Interferon a2b (Intron A; Schering-Plough).
 
Staining of PBMCs and Sorted Granular Cells.
 
PBMCs were
stained with anti-CD14 PE (BD Biosciences) and sorted (FACS-
Vantage™; Becton Dickinson) based on granularity (high for-
ward side scatter/side light scatter) and lack of CD14 expression.
Both unsorted PBMCs and sorted cells were allowed to adhere
for 1 h on slides previously coated with 0.1 mg/ml of poly-L-
lysine (Sigma-Aldrich) for 1 h at room temperature and fixed
with 4% paraformaldehyde. After quenching with PBS-glycine
(50 mM), cells were permeabilized with Triton X-100 (0.1%), 10
min. They were subsequently washed with PBS-saponin (0.2%)
and quenched with PBS-BSA-gelatin fish before staining with
FITC-conjugated mouse anti-human myeloperoxidase (DakoCy-
tomation). Cytospins of unsorted and sorted cells were stained
with Giemsa or treated with p-phenylenediamine and catechol to
detect cytoplasmic myeloperoxidase according to the method de-
scribed by Hanker et al. (21). Fluorescence labeled cells were
mounted in fluoromount mounting medium (Southern Biotech-
nology Associates, Inc.) for confocal microscopy. All micrographs
were recorded using a confocal microscopy system equipped with
three Ar488, Kr568, and HeNe633 lasers (TCS-SP; Leica) as well
as spectrophotometers using the objectives 63
 
 
 
 or 100
 
 
 
 PL
APO with zoom 2.
 
Patient Characteristics.
 
30 pediatric SLE patients, 18 females
and 12 males, were enrolled in the study Dec 2001–June 2002.
Of these, 13 were Hispanic, 8 African-American, 6 Asian, and 3
 
Caucasian. This distribution reflects the overall ethnicity of our
SLE population in North Texas. The detailed clinical informa-
tion is provided as online supplemental Table S1.
 
Microarray Procedures.
 
Total RNA extracted from samples
was used to generate cRNA target using the ENZO kit, subse-
quently hybridized to human U95A oligonucleotide probe array
(Affymetrix, Inc.) according to standard protocols provided by
the manufacturer.
 
Data Analysis.
 
An absolute expression analysis was performed
using Affymetrix MAS 5.0, and the data from 12,626 genes was
imported into GeneSpring software (Silicon Genetics) for further
analyses. Differentially expressed genes were selected as described
in Results.
 
Online Supplemental Material.
 
Differentially expressed genes
were selected as described in Results. Supplemental Table
S1 is available at http://www.jem.org/cgi/content/full/jem.
20021553/DC1.
 
Results
 
Gene Expression in Blood Leukocytes.
 
To identify gene
expression signatures unique to SLE, we analyzed Ficoll-
separated blood mononuclear cells (PBMCs) from three pe-
diatric cohorts: 9 healthy children (age 13 
 
 
 
 4 yr), 30 SLE
patients (age 13 
 
 
 
 3 yr), and 12 patients with juvenile
chronic arthritis (JCA; age 10 
 
 
 
 3 yr). SLE patients be-
longed to four ethnicities and included 12 males and 18 fe-
males. One patient had been in complete remission (SLE
Disease Activity Index [SLEDAI] 
 
 
 
 0) for more than 2 yr,
11 patients had minimal disease activity (SLEDAI 
 
 
 
 2–4),
10 patients had intermediate disease activity (SLEDAI 
 
  
 
6–10)
and 8 patients had high disease activity (SLEDAI 
 
 
 
 11–20).
The clinical features are provided as supplementary data
(Table S1). Of the 12 patients with JCA, 4 had pauci-artic-
ular, 5 poly-articular, and 3 the systemic form of the disease.
PBMC cRNA was hybridized to U95AV2 Affymetrix
oligonucleotide microarrays containing 12,561 human
genes and the data were analyzed with the GeneSpring
software. Up to 5,000 genes were expressed, with 4,600
being common to all children. The pattern of expression
was remarkably stable among individuals. SLE patients and
healthy donors were analyzed using a parametric statistical
group comparison incorporating the global error method.
Using the most stringent multiple comparison correction
for controlling Type I error (Bonferroni correction), 15
genes were found differentially expressed (P 
 
  
 
0.1) be-
tween these two populations and highly up-regulated in
SLE patients. Strikingly, 14 of 15 genes (Table I) represent
either well-known or newly identified targets of interferon.
The single non-IFN–regulated gene was defensin, a major
product of immature neutrophils. Applying a more liberal
correction to the pairwise tests (Benjamini and Hochberg
correction) yielded 18 additional genes, 12 of which are
known to be IFN-regulated and 4 neutrophil-specific (Ta-
ble I). Use of the more liberal multiple comparison correc-
tive technique yields an expanded list of genes differentially
expressed (P 
 
  
 
0.05) between these two groups to 374
(Fig. 1). Among these, 210 genes were up-regulated and
141 genes were down-regulated in a majority of patients.T
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PBMCs from the only patient in complete remission dis-
played a global gene pattern indistinguishable from that of
the healthy controls. Indeed, when compared with the nine
healthy individuals, hierarchical clustering spontaneously
placed this patient next to the healthy children. Further-
more, patients with JCA did not display the same pattern of
 
Table I.
 
Genes Significantly Up-regulated in SLE Patient’s Blood Mononuclear Cells
 
GenBank
accession no. Description Family Function
P value
Bonferroni
P value Benjamini
and Hochberg
M87434 71 kD 2
 
 
 
5
 
 
 
 OIAS IFN Antiviral
 
 
 
0.00001
 
 
 
0.0001
AB000115 GS3686 IFN Unknown
 
 
 
0.0001
 
 
 
0.0001
D28195 Hep C p44 IFN Unknown 0.0001
 
 
 
0.0001
X57352 1-8U IFN Unknown
 
 
 
0.0002
 
 
 
0.0001
M33882 MX1 IFN GTP-ase antiviral
 
 
 
0.0003
 
 
 
0.0001
M30818 MX2 IFN GTP-ase antiviral
 
 
 
0.002
 
 
 
0.0003
U66711 RIGE/TSA1 IFN Signal transduction
 
 
 
0.01
 
 
 
0.001
AB006746 Phospholipid
scramblase
IFN Transbilayer migration
of phospholipids
 
 
 
0.03
 
 
 
0.003
L12691 DEFA3 Neut Antibacterial
 
 
 
0.03
 
 
 
0.003
X04371 2
 
 
 
5
 
 
 
 OIAS E18 isoform IFN Antiviral degradation of RNA
 
 
 
0.03
 
 
 
0.003
AL047596 EST Hute 1 IFN Unknown
 
 
 
0.05
 
 
 
0.005
U53831 IRF 7b IFN Transcription activator
 
 
 
0.05
 
 
 
0.005
M97935 ISGF-3 IFN Transcription factor 0.06
 
 
 
0.005
AL022318 Phorbolin 1 like IFN Unknown mRNA editing? 0.06
 
 
 
0.005
U72882 IF p35 IFN Unknown 0.07
 
 
 
0.005
L13210 MAC-2-BP IFN Host defense cell adhesion
 
 
 
0.02
X99699 XIAP associated
factor 1
IFN Proapoptotic
 
 
 
0.02
M13755 ISG-15 IFN Unknown
 
 
 
0.03
X69910 p63 transmembrane
protein
Unknown Membrane trafficking
 
 
 
0.03
X54486 C1 inhibitor IFN C1 esterase inhibition
 
 
 
0.03
X55988 Eosinophil derived
neurotoxin
Neut Ribonuclease
 
 
 
0.04
L09708 Complement
component 2
IFN Complement cascade
 
 
 
0.05
AF016903 Agrin IFN Aggregation of signaling
proteins at the neurological
and immunological synapsis
 
 
 
0.05
X57522 TAP1 IFN Antigen presentation
 
 
 
0.05
AF026939 Cig 49 IFN Unknown
 
 
 
0.05
AI126134 EST similar
to calgranulin
Neut Calcium binding
protein proinflammatory
 
 
 
0.05
AJ225089 TRIP 14 OIAS IFN Antiviral degradation of RNA
 
 
 
0.05
U37518 TRAIL IFN Apoptosis
 
 
 
0.05
M84562 Formyl peptide
receptor-like
Neut Neutrophil activation
and chemotaxis
 
 
 
0.05
AL036554 DEFA1 Neut Antibacterial 0.05
Z38026 FALL-39 Neut Antibacterial 0.06
AB025254 Sim to
Dros. Tudor
IFN Unknown 0.06
M24594 IFI-56 IFN Unknown 0.06T
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expression for these genes. Thus, we have identified a pat-
tern of gene expression that distinguishes SLE from healthy
individuals and from other autoimmune diseases. This rep-
resents a remarkable finding, as SLE is characterized by sig-
nificant clinical heterogeneity. A closer analysis of the al-
tered genes permitted the identification of several signatures.
 
The IFN Signature.
 
The initial analysis of SLE up-regu-
lated genes showed a striking predominance of genes
known to be up-regulated in response to type I IFN. To
further delineate whether other genes up- and down-regu-
lated in SLE leukocytes may be previously unrecognized
IFN targets, we analyzed the genes expressed in healthy
PBMCs cultured with IFN-
 
 
 
 (1,000 U/ml, 6 h). Overall,
IFN-
 
 
 
 altered the expression of 127 genes, up-regulating
92 of them. 46 of these 92 genes were found up-regulated
in SLE PBMC. Fig. 2 illustrates the expression of 36 up-
regulated and 13 down-regulated genes in both SLE
PBMC (left panel) and healthy PBMC exposed to IFN-
 
 
 
(right panel).
The most commonly up-regulated transcripts (in 28/29
active patients) corresponded to three genes known to be
IFN-induced (Cig5, Cig49, and Hepatitis C associated mi-
crotubular aggregate protein) and a novel gene (GS3686),
which our in vitro studies show as being IFN-regulated as
well. The well-known type I IFN response genes MX1
and oligoadenylate synthetase were up-regulated in 26 and
21/29 active SLE patients, respectively.
Further analysis of IFN-
 
 
 
 up-regulated genes identified
from both in vitro cultures and patient’s PBMCs revealed
several genes coding for molecules relevant to SLE, includ-
ing autoantigens (Ro-52 and Lamin 1b) and molecules
involved in complement cascade such as C2- and C1-
inhibitor. Furthermore, 17/29 SLE PBMCs showed up-
regulation of phospholipid scramblase (22), a molecule im-
plicated in the transbilayer movement of plasma membrane
phospholipids occurring upon cell injury or apoptosis (23).
In this context, TRAIL, an TNF-induced potent effector
of apoptosis (24), was up-regulated in 12 of the patients
(Fig. 2 A). XAF1 (XIAPAF1), a recently described mole-
cule involved in TRAIL-induced apoptosis (25), was also
found to be IFN-induced in vitro and up-regulated in 17/29
SLE patients (Fig. 2 A).
DC-LAMP, a lysosomal transport related molecule spe-
cifically expressed in mature DCs (26), was up-regulated by
Figure 1. SLE signature. Hierarchical clustering
of gene expression data by blood leukocytes of 9
healthy children, 30 with SLE, and 12 with juve-
nile chronic arthritis including 3 systemic arthritis.
The SLE patients have been ranked according to
their SLEDAI at time of blood draw. Each row
represents a separate gene and each column a sepa-
rate patient. 374 transcript sequences have been se-
lected which were differentially expressed in SLE
by comparison to healthy patients. The normalized
expression index for each transcript sequence
(rows) in each sample (columns) is indicated by a
color code. Red, yellow, and blue squares indicate
that expression of the gene is greater than, equal to
or less than the mean level of expression across 9
healthy controls. The scale extends from fluores-
cence ratios of 0.25 to 4.0. Full raw data expression
information of the genes in this figure is available
upon request to the corresponding authors.T
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IFN in vitro and found overexpressed in 16/29 SLE PBMCs.
Thus, the global gene analysis correlates with our recent
finding demonstrating that SLE blood contains monocytes
that function as DCs in an IFN-
 
 
 
–dependent fashion (15).
Finally, a majority of patients (25/29) overexpressed the
IFN-regulated chemokine MCP-1. Accordingly, the levels
of MCP-1 protein in 25 available SLE serum samples cor-
related remarkably well with the level of MCP1 gene ex-
pression (
 
r
 
 
 
  
 
0.60, P 
 
  
 
0.0007; Fig. 2 B), thereby corrobo-
rating the global gene analysis approach. Taken together
the present data reinforce the critical role of interferon in
the etiopathogenesis of SLE.
 
Lymphocytes and DCs.
 
Numerous lymphocyte-specific
transcripts were decreased in SLE PBMCs, an expected
finding in line with the lymphopenia that characterizes hu-
man SLE. In particular, the pan-T cell genes TCR
 
 
 
/
 
 
 
,
 
p56 
 
lck
 
, CD3
 
 
 
 chain, and SAP were down-regulated in
many patients (Fig. 3 A). Pan-B cell (CD20, CD79a/b, and
CD22) and naive B cell markers (IgD) were dowregulated
in 14 patients.
On the contrary, 
 
 
 
2 fold up-regulated transcription of
IgG and IgA was found in 14 and 7 patients, respectively,
and correlated with their number of circulating plasma
blasts/cells (Fig. 3, B and C). There was a strong correla-
tion between increased IgG transcription and gender, as
2/12 males and 12/18 females up-regulated this molecule.
Additionally, down-regulated (
 
 
 
2 fold) IgG transcripts
were found in 5/12 males but in only 1/18 females (P 
 
 
 
0.009, Chi square with exact P value).
CD161, a marker of NK/NKT cells, was found to be the
most significantly decreased (19/30 patients) lineage marker.
Two genes specific for activated DCs, DC-LAMP and
Figure 2. IFN signature. (A) Ac-
tive SLE patients leukocytes (left
panel) display 36 IFN-up-regulated
and 13 down-regulated transcript se-
quences. The same genes are altered
in healthy PBMCs cultured in vitro
with IFN-  (right panel). Median
expression and the number of pa-
tients who display more than two-
fold increase in gene expression. **
Significant after Bonferroni correc-
tion,  * significant after Benjamini
and Hochberg correction. (B) Levels
of MCP-1 protein in the 25 avail-
able SLE serum samples correlate
with the MCP-1 gene expression.T
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CD83, were up-regulated in 16 and 6 patients, respectively.
Furthermore, TAP1, a critical molecule for MHC class I an-
tigen presentation, was up-regulated in 6 patients (Fig. 2 A)
as well as in the in vitro IFN-treated PBMCs, thus extend-
ing the list of IFN-regulated genes. This pattern of DC acti-
vation molecules is consistent with our previous report
demonstrating unabated DCs induction by SLE serum (15).
 
Signature of Granulopoiesis.
 
Among the SLE distinctive
up-regulated genes, the highest overexpression (over a
100-fold) was found in granulopoiesis-related genes. These
could be divided into three categories: enzymes and their
inhibitors, bactericidal proteins, including defensins, as well
as other molecules such as calcium-binding proteins (Fig. 4
A). 25 patients overexpressed these genes. Accordingly, the
average transcription levels of MPO and elastase, two
genes preferentially transcribed within the earliest granulo-
cytes (myeloblasts and promyelocytes; reference 27), were
8- and 12-fold higher, respectively, than controls. Con-
versely, formyl-methionyl-leucyl-phenylalanine receptor-
like (F2RPA), a transcript characteristic of mature (band,
segmented and polymorphonuclear) cells, was up-regu-
lated only 1.8-fold in SLE compared with healthy controls.
Indeed, the neutrophil-specific gene most significantly up-
regulated in our patients was defensin-3, a transcript
mainly present at the intermediate (myelocyte-metamyelo-
cyte) stages of maturation and absent in polymorphonu-
clear cells (27).
The expression of early neutrophil genes was surprising,
as Ficoll-separated PBMCs do not normally contain granu-
locytes. The analysis of flow cytometry data showed that all
the patients expressing granulopoiesis-related genes had a
population of highly granular cells (Fig. 4 B). A more de-
tailed analysis of these cells has been performed in two ad-
ditional patients (#31 and #32, not included in the mi-
croarray analysis). Fig. 5 shows the scattergram of the
PBMCs from patient #31 demonstrating the presence of
granular cells (Fig. 5 A) and a Giemsa staining of the same
PBMCs (Fig. 5 B) displaying lymphoid and monocytoid-
shaped mononuclear cells. Indeed the staining of these
PBMCs with a FITC-labeled anti-MPO antibody reveals
the presence of two strongly positive cells corresponding to
a myelocyte and a band neutrophil (Fig. 5 C). Without the
MPO staining, the myelocyte would have been morpho-
logically undistinguishable from a monocyte. We next
sorted the high scatter cells and confirmed their lack of ex-
pression of monocyte (CD14) lineage markers (Fig. 5 D).
Giemsa staining of the sorted cells revealed the presence of
cells at all stages of granulocyte development, including
pro-myelocytes, myelo- and meta-myelocytes, early and
late bands as well as segmented neutrophils (Fig. 5 E). All
these cells actually expressed MPO (Fig. 5 F). The PBMCs
from an additional patient (#32) were further analyzed by
scattergram (Fig. 5 G) and Giemsa staining (Fig. 5 H). An
enzymatic assay to reveal MPO (21) was performed and
showed the presence of many intensely positive cells. A
single field in Fig. 5 I shows three positive cells, one of
them displaying a nucleus morphologically undistinguish-
able from two monocytes present in the same field. The
presence of immature granulocytes correlated with the
granulopoiesis signature (Fig. 4 C). Furthermore, the data
gathered in Table II demonstrates that the granulopoiesis
signature cannot be attributed to steroid treatment, as sev-
eral newly diagnosed, untreated patients displayed both the
signature and the cells. Table II also shows that the IFN
and granulopoiesis signatures are not necessarily associated.
Whether these cells are essential to SLE pathogenesis re-
mains to be established. However, some of the life-threat-
ening complications of SLE, such as renal failure, vasculitis,
and CNS involvement, could actually be related to the re-
lease of neutrophil proteolytic enzymes (28).
Microarrays for SLE Patient Follow-up. Out of 33 SLE-
specific genes selected with the Benjamini and Hochberg
multiple comparison correction, we could identify a set of
10 whose expression correlated with disease activity ac-
cording to the SLEDAI (Table III, Fig. 6). Of these, 8
genes were IFN-regulated and 2 were neutrophil-related.
Expression of every one of these genes correlated better
with disease activity than serum levels of anti–double-
stranded DNA antibodies, a hallmark of SLE (Fig. 6). The
most significant correlation (P    0.001,  r     0.55) was
Figure 3. Lymphoid signature: T and B lymphopenia with hypergam-
maglobulinemia. (A) T cell genes, and the Ig genes. Median expression
and the number of patients who display more than twofold increase (red)
or decrease (blue) in gene expression. (B) Flow cytometry analysis of pu-
rified B cells showing the high frequency of CD19 CD38high plasma-
blasts. (C) IgG transcript levels correlate with plasmablast numbers.T
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found with the gene encoding F2RPA, which mediates the
chemotactic activities of defensins (29) and is mainly tran-
scribed within segmented and polymorphonuclear cells (26;
Fig. 6). Longitudinal follow-up of these gene expression
levels in our patients will allow us to determine their signif-
icance in disease flare prediction. This is of particular im-
portance, as there are no parameters other than clinical
symptoms to predict SLE flares.
Glucocorticoid Treatment Extinguishes the IFN Signature in
SLE Leukocytes. Glucocorticoids (GCs) constitute the
standard therapy of SLE. We usually administer low dose
oral prednisone ( 0.5 mg/kg/day) to avoid the consider-
able side effects of this type of medication. This therapy is
unfortunately insufficient to keep children with SLE in re-
mission, and flaring of the disease is frequent. Flares can be
controlled with high dose glucocorticoid intravenous
pulses (30 mg methylprednisolone/kg/day for 3 con-
secutive days). We analyzed the PBMCs of three patients
before and after such treatment. As shown in Fig. 7, all pa-
tients showed a highly significant down-regulation of IFN-
regulated genes after the pulse. Yet, granulocyte-related
genes were not extinguished. These data therefore raise the
intriguing possibility that glucocorticoids, broad inhibitors
of immune cell functions (30), may act in SLE treatment
through the blocking of IFN activity.
Discussion
This study demonstrates that the majority (29/30) of
children suffering from SLE display a signature of IFN ex-
posure in their blood cells, therefore reinforcing the role of
IFN-  in the pathogenesis of this disease (15, 31, 32).
Thus, in spite of being clinically heterogeneous, all active
SLE patients regardless of age, gender, and ethnicity have a
signature of IFN exposure. Importantly, many of the IFN- 
targets represent molecules that have long been associated
to SLE pathogenesis. For example, the IFN up-regulated
Ro-52 is one of the hallmark antigens in this disease, and
autoantibodies against this molecule are routinely measured
in SLE patients (1, 2). The up-regulation of IFN-induced
Figure 4. Granulopoiesis sig-
nature. (A) Genes have been di-
vided into three categories: en-
zymes and their inhibitors,
bactericidal proteins, and others.
Median expression and the num-
ber of patients who display more
than twofold increase (red) in
gene expression. ** Significant
after Bonferroni correction, *
significant after Benjamini and
Hochberg correction. (B) Pres-
ence of granular cells in leuko-
cytes that display granulopoiesis-
related RNA. Flow cytometry
analysis (forward scatter vs. side
scatter) of Ficoll-separated
mononuclear cells. The gated
cells are immature neutrophils.
(C) Correlation between the de-
fensin   (DEF3) levels and the
numbers of cells gated as shown
in B.T
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phospholipid scramblase, TRAIL and XIAPAF1 provides a
link to the current association of SLE with dysregulation of
apoptosis and/or handling of apoptotic cells (33). Increased
expression of genes coding for TAP1 and DC-LAMP may
be relevant for autoantigen presentation. Our studies also
show that high dose IV steroid treatment, one of the most
effective treatments of SLE flares, efficiently down-regulates
the IFN-  signature in SLE leukocytes. This reinforces the
importance of targeting IFN to treat this disease, especially
as most available therapies, especially glucocorticoids, carry
severe morbidity and dramatic life-long side effects, partic-
ularly in children.
Microarray analysis appears to provide a more faithful in-
dication of exposure of blood cells to IFN than the mea-
surement of IFN in SLE patient’s serum. In our previous
study, we detected increased levels of IFN-  by ELISA in
Figure 5. (A) FSC/SSC analysis of SLE patient #31 PBMCs; (B) Giemsa staining of the same PBMCs (arrow indicates possible early granulocyte); (C)
confocal analysis of anti-MPO FITC staining of the same PBMCs. A late band/early segmented granulocyte and a metamyelocyte (arrow) are strongly
positive for MPO; (D) sorted CD14 negative granular cells from panel A; (E) Giemsa staining of the sorted cells showing multiple mononuclear cells, in-
cluding a myelocyte (arrow) and several metamyelocytes, bands and segmented neutrophils; (F) confocal analysis with anti-MPO FITC antibodies show
that  95% of the sorted cells express MPO; (G) FSC/SSC analysis of the PBMCs for a second SLE patient (#32); (H) Giemsa staining of the PBMCs
from the same patient; (I) three cells from the same patient’s PBMCs, including one with monocytoid nucleus (arrow), are positive for MPO.T
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10/20 patients (15). Our current microarray analysis re-
vealed that 29/30 patients had evidence of exposure to this
cytokine. Several factors may contribute to the lower sensi-
tivity of the IFN serum assay(s). SLE patients, for example,
have been shown to display anti-IFN antibodies in their se-
rum (34) that may interfere with ELISA measurements.
Additionally, the antibody used for ELISA detection may
not react with all the IFN species that may circulate in the
blood. Finally, our lack of detection of significant IFN- 
transcripts in the SLE patient’s PBMCs and the reported
presence of plasmacytoid DCs in the skin lesions of SLE
patients support that this cytokine may be mainly produced
in the patient’s tissues (35, 36).
In addition to the IFN signature, we observed a sig-
nificant up-regulation of granulocyte-specific transcripts
within SLE-PBMC RNA. This “granulocyte signature”
Table II. Raw Expression Data from Representative IFN and Granulopoiesis Signature Genes in a Subset of SLE Patients
Granulopoiesis signature IFN signature
SLE
patient no.
SLE
DAI Treatment
% 
Granulocytes MPO Elastase DEF3 DEFA1 F2RPA 2 5  OIAS GS3686
HepC
p44 MX1
30 20 N* 22.1 249
(3.2)
312
(3.1)
15704 
(4.5)
5064
(6.8)
843 
(4.1)
2876
(3.6)
4416
(25.2)
5176 
(14.5)
3775 
(10.0)
27 12 Y 14.6 3539
(49.3)
5847
(63.6)
26594 
(8.4)
29984
(43.6)
192 
(1.0)
1157
(1.6)
1384 
(8.6)
1569
(4.8)
666 
(1.9)
26 12 N* 15.4 2203
(33.6)
6115
(73.0)
11414 
(3.9)
11454
(18.3)
333 
(1.9)
1842 
(2.8)
1334
(9.0)
744
(2.5)
1337
(4.2)
25 12 N* 11.0 862 
(9.8)
2813
(25.0)
59928
(15.4)
30013
(35.8)
665
(2.9)
1615 
(2.9)
3285
(16.6)
2074
(5.2)
3903
(9.2)
24 12 N* 4.3 183 
(2.6)
419
(4.7)
12591
(4.1)
1539
(2.3)
366 
(2.0)
2098
(3.0)
2005
(12.8)
1784
(5.6)
2976 
(8.9)
23 11 N* 13.7 754
(6.9)
1297
(9.3)
53375 
(11.1)
19953 
(19.2)
696 
(2.5)
1418
(1.3)
1173 
(4.8)
1830 
(3.7)
1652
(3.1)
22 10 Y 30.5 3765
(53.7)
6911
(77.0)
20815
(6.7)
23042
(34.4)
365 
(2.0)
1704 
(2.4)
2171
(13.8)
1090 
(3.4)
1342
(4.0)
17 8 Y 8.2 963 
(9.6)
1055
(8.2)
32365
(7.3)
3701 
(3.9)
449 
(1.7)
4071 
(4.0)
3266 
(14.5)
2142
(4.7)
1127 
(2.3)
15 8 Y 6.5 168
(2.3)
285
(3.0)
18265 
(5.6)
3700 
(5.3)
531 
(2.8)
3463
(4.7)
2387
(14.5)
2741 
(8.2)
4385
(12.4)
10 4 Y 2.2 722 
(10.0)
1552
(16.8)
27089
(8.5)
11268
(16.3)
388
(2.0)
1299 
(1.8)
703
(4.3)
795 
(2.4)
826
(2.4)
29 18 N 0.7 70
(1.0)
56 
(0.6)
2414 
(0.8)
463
(0.7)
133
(0.7)
2822
(4.0)
3751 
(24.1)
2391
(7.5)
2944 
(8.8)
14 8 Y 1.1 68
(0.8)
52
(0.5)
10499 
(2.8)
1035
(1.3)
265
(1.2)
4360
(5.0)
5211 
(27.2)
3627
(9.3)
5214 
(12.7)
72 N * 0.6 107 
(1.6)
88
(1.0)
6026
(2.1)
1868
(3.0)
144 
(0.8)
1713 
(2.6)
1872 
(12.8)
1132 
(3.8)
1450 
(4.6)
5 2 Y 0.4 56 
(0.7)
82 
(0.8)
1827 
(0.5)
479
(0.6)
462
(2.2)
2066 
(2.5)
2601 
(14.4)
1562
(4.5)
2676 
(6.9)
4 2 Y 0.7 77
(1.1)
12 
(0.1)
390 
(0.1)
31
(0.05)
204
(1.1)
1742 
(2.4)
1298
(8.2)
1454 
(4.5)
1021 
(3.0)
9 healthy donors  0.1 71
  22
94
  88
3221
  3004
716
  947
186 
  90
712 
  116
158
  49
322
  71
338
  67
The granulopoiesis signature is independent of treatment and is found only in patients with immature granulocytes. Raw signal values with a “per
chip” normalization applied are shown in bold; Normalized values are shown in italics. N*, new untreated patient; N, untreated patient; Y, treated
patient. % granulocytes: fraction of granular cells from the gated viable cells of the PBMCs isolated over Ficoll.T
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was traced down to the presence of highly granular cells
that copurified with mononuclear cells during density gra-
dient centrifugation. Low density neutrophils have been
previously described in the blood of patients with SLE (37).
The highly granular cells that we observe in our patients
seem to correspond, however, to granulocytes at different
stages of maturation, from myelocytes to polymorphonu-
clear cells. Giemsa and MPO stainings of PBMCs and
CD14-negative granular cells, together with the granulo-
cyte-specific gene transcription pattern that we obtained,
support indeed the predominance of immature cells (27).
Low density, mature granulocytes may be contributing,
however, to the disease pathogenesis, as the transcription
levels of F2RPA, a mature neutrophil transcript, displayed
the best correlation with SLE disease activity as measured
by the SLEDAI.
Table III. Correlation of Gene Expression with Disease Activity 
Measured by SLEDAI
Gene Family r P value
F2RPA Neutr 0.55 0.0014
ISG15 IFN 0.52 0.003
Cig49 IFN 0.50 0.0048
HepC microtubular Agg IFN 0.49 0.0059
TRIP 14 IFN 0.48 0.0069
MX1 IFN 0.43 0.01
Phospholipid scramblase 1 IFN 0.41 0.02
XIAPAF 1 IFN 0.41 0.02
DEFA3 Neutr 0.39 0.03
RIGE/TSA 1 IFN 0.38 0.03
r, Pearson correlation coefficient.
Figure 6. Correlation of gene
expression and disease activity as
measured by SLEDAI. Two
IFN-induced genes (Cig49 and
phospholipid scramblase 1) and
a granulocyte-related gene
(F2RPA) correlate significantly
with SLEDAI. These particular
genes are selected from those in
Table III to illustrate different
families. By comparison, there is
no correlation of serum levels of
anti-double stranded DNA anti-
bodies with disease activity.
Figure 7. Extinction of IFN signature after steroid infusion. Analysis of
PBMCs from 3 patients (#30, 25, and 5, see online Table S1) before and
after (1–4 d) treatment with high dose intravenous GC (1g/day for 3 d).
All patients show down-regulation of IFN-regulated genes. P values on
the right indicate significance of the gene expression level before and after
GC (paired t test). Patient #5 did not display granulopoiesis signature be-
fore high dose GC therapy, 2 other patients do not show alteration in
granulocyte-related genes following high dose GC therapy.T
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Stress and demargination are a well known cause of neu-
trophilia, but they usually yield neutrophils with character-
istics of polymorphonuclear cells (38). Demargination is
also associated with steroid treatment. The cells that we de-
scribe, however, preferentially transcribe genes characteris-
tic of immature bone marrow precursors. Furthermore,
these cells are present not only regardless of steroid treat-
ment, but we find them at the highest levels in new, un-
treated patients (Table II).
Our in vitro experiments support that mononuclear
cells, i.e., monocytes and lymphocytes, are the main cells
responsible for the IFN-  signature. In fact, PBMCs from
healthy donors, which do not display the low density gran-
ulocyte population, up-regulate the same set of genes upon
incubation with IFN for 6 h. Additionally, the IFN signa-
ture is evident in five patients who lack the highly granular
population and therefore the neutrophil-specific genes (Ta-
ble II). Further experiments to assess the contribution of
individual cell population to the SLE blood signatures are
currently underway.
Hypergammaglobulinemia and immune complex for-
mation represent two classical features of SLE. Pediatric
SLE patients, however, display reduced numbers of blood
mature lymphocytes and a concomitant expansion of
plasma cell precursors (9). Our current studies confirm
these alterations, as we found down-regulation of pan-
lymphocyte markers. Additionally, up to half of our
patients displayed a blood plasma cell signature with in-
creased transcription of immunoglobulin genes. Interest-
ingly, there was a statistically significant correlation be-
tween increased IgG transcription and female gender, as of
the 12 males in our study, only 2 had increased blood IgG
while 5 showed a global reduction of Ig transcripts. This is
the only gender associated signature in our study, as both
IFN and granulocyte-specific genes were equally present in
males and females.
We propose that SLE prone patients cells, perhaps as the
result of complex genetic alterations associated to the dis-
ease, produce IFN in an unabated fashion. Alternatively
SLE patients may carry a persistent stimulus, i.e., a virus,
that may drive overproduction of IFN. Regardless of the
mechanism leading to its excess, IFN turns on the adaptive
immune system through the activation of DCs, leading to a
break of tolerance to self antigens. Concomitantly, IFN
may mobilize the innate immune system, as illustrated by
the accumulation of low-density neutrophils in the circula-
tion, possibly via induction of endogenous G-CSF (39, 40).
These cells are rarely found in the blood under normal cir-
cumstances, and their presence in large amounts may reflect
their recruitment to sites of inflammation where immune
complexes are deposited. There, they may contribute to
tissue damage through the release of potent proteases, pos-
sibly following immune complex triggering (41). Indeed, it
has been shown that neutrophils may be associated to kid-
ney disease as well as to vasculitis in SLE patients (42, 43).
Furthermore, immature neutrophils may be dying outside
their natural microenvironment and thus may represent a
major source of nuclear autoantigens (44). The latter will
be captured by IFN-  activated DCs and presented to au-
toreactive lymphocytes, thus closing the circle.
The present study, using SLE as a prototype autoim-
mune disease, demonstrates the power of analyzing blood
samples with microarrays. Indeed, white blood cells are im-
mune cells from either the innate immune system (granulo-
cytes, NK cells) or the adaptive immune system (T and B
lymphocytes) or both (monocytes and DCs). Our study
shows that microarray analysis of blood may identify etio-
pathogenic factors and predictors of disease activity. This
approach may be applied to many other diseases of the im-
mune system and beyond.
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